Abstract: Somatostatin analogues, such as octreotide, depreotide and so on, having long-time and high affinity with somatostatin receptors(SSTR) and labeled by radionuclides, can be used in SSTR scintigraphy and treatment of tumors expressing SSTR. Moreover, Lymphoma express SSTR(SSTR2 and SSTR3). A series of clinical and experimental results showed SSTR scintigraphy is an interesting way to evaluate the diagnosis, staging, treatment and prognosis of lymphoma, and a supplemental tool of diagnosing and judging lymphoma with conventional X-rays imaging, ⁶⁷Ga and PET. Whereas, the application of radionuclide-labeled somatostatin analogues in treatment of lymphoma should be cautiously performed. Recently it is a concerned question how the patients suffering from lymphoma can have the most profits and the least side-effects from the treatment of radionuclide-labeled somatostatin analogues.